Bio Impact Capital LLC Cullinan Oncology, Inc. Transaction History
Bio Impact Capital LLC
- $540 Million
- Q1 2025
A detailed history of Bio Impact Capital LLC transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Bio Impact Capital LLC holds 7,648,268 shares of CGEM stock, worth $57.5 Million. This represents 10.72% of its overall portfolio holdings.
Number of Shares
7,648,268
Previous 7,648,268
-0.0%
Holding current value
$57.5 Million
Previous $93.2 Million
37.85%
% of portfolio
10.72%
Previous 13.93%
Shares
2 transactions
Others Institutions Holding CGEM
# of Institutions
155Shares Held
68.5MCall Options Held
15.6KPut Options Held
17.9K-
Bvf Inc San Francisco, CA5.75MShares$43.2 Million1.91% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.86MShares$29 Million0.74% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$26.7 Million0.0% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$25.7 Million15.23% of portfolio
-
Lynx1 Capital Management LP San Juan, PR3.22MShares$24.2 Million9.0% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $343M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...